drugset / Trial / NCT06053840

An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients with Severe Insomnia

NCT06053840

Phase 4 Completed 100 enrolled Pharmanovia
NaSingle-groupOpen-labelTreatment

Summary

The primary aim of this Real-World Evidence trial is to establish whether short-term (2 weeks) treatment of Chloral Hydrate is effective in patients with severe insomnia which is interfering with normal daily life, and where other behavioural and pharmacologic therapies have failed in a real world setting.

Timeline

Start
2023-09-01
Primary completion
2024-04-24
Completion
2024-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Chloral Hydrate Small molecule 430 mg Oral
Subject Chloral Hydrate Small molecule 860 mg Oral

Indications